Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Research & Development (2016 - 2025)

Karyopharm Therapeutics' Research & Development history spans 14 years, with the latest figure at $27.7 million for Q4 2025.

  • For Q4 2025, Research & Development fell 16.92% year-over-year to $27.7 million; the TTM value through Dec 2025 reached $125.6 million, down 12.3%, while the annual FY2025 figure was $125.6 million, 12.3% down from the prior year.
  • Research & Development reached $27.7 million in Q4 2025 per KPTI's latest filing, down from $30.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $45.8 million in Q3 2021 to a low of $27.7 million in Q4 2025.
  • Average Research & Development over 5 years is $35.9 million, with a median of $35.0 million recorded in 2024.
  • The largest YoY upside for Research & Development was 30.39% in 2022 against a maximum downside of 31.54% in 2022.
  • A 5-year view of Research & Development shows it stood at $44.0 million in 2021, then fell by 29.7% to $30.9 million in 2022, then rose by 27.31% to $39.4 million in 2023, then fell by 15.44% to $33.3 million in 2024, then dropped by 16.92% to $27.7 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Research & Development are $27.7 million (Q4 2025), $30.5 million (Q3 2025), and $32.8 million (Q2 2025).